News
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide, a PTHR1 Agonist Entering phase 3 for the Treatement of Hypoparathyroidism, in Chicago on June 16, 2023
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will host an in-person key opinion leader (KOL) event on eneboparatide, the company’s investigational lead product candidate...
Primo1D Teams Up with Decathlon to Bring Garment Tracingto the Recycling Sector Thanks to its E- Thread™ Technology
Primo1D, a world leader in smart embedded Radio Frequency Identification (RFID) tags, today announced a paradigm shift in the way textiles are recycled. By using Primo1D’s RFID E-Thread™ embedded into Decathlon garments, the company reached a major milestone to...
Amolyt Pharma Launches Public Awareness Campaign to Honor World Hypoparathyroidism Awareness Day
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced its support of World Hypoparathyroidism Awareness Day, which is observed annually on June 1. Complete Press Release Amolyt Pharma
Ciliatech raises €3.5M in Series A funding
Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, today announces it has raised €3.5M (approx. $4M) from BNP Développement, Kreaxi and Bernard Chauvin, all historical investors. This Series A funding is composed...
Ciliatech reports positive clinical results on novel glaucoma implant, CID, in 24-month post-operative follow-up
Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, today announces the positive results of a 24-month post-operative follow-up on a clinical trial of CID, its first generation Cilio-scleral Inter-positioning...
Previa Medical raises €2.1 million for AI solution to prevent sepsis
Previa Medical, a deeptech start-up specialized in developing predictive medical devices for alerting healthcare providers to the risk of potential complications, today announces it has raised €2.1 million ($2.2M) in seed funding for SEPSI-SCORE©, a specialist...
Novel Hydrogen transport and storage technology developer HySilabs raises 13€ million in its series A
HySiLabs today announced a EUR 13 million Series A financing led by Equinor Ventures, and joined by the European Innovation Council Fund, EDP Ventures and PLD Automobile, with the support of historical investors Kreaxi, Région Sud Investissement and CAAP Création. The...
Amolyt Pharma annonces research agreement and licensing option with XOMA
Amolyt Pharma (“Amolyt,” “Amolyt Pharma” or the “Company”), a global company specialized in developing innovative therapies for rare endocrine and related diseases, today announced that the Company has entered into a research agreement and licensing option with XOMA...
Amolyt Pharma announces $ 138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly. Complete press...
OREGA Biotech enters into an Exclusive License Agreement with Genmab for a novel immuno-oncology antibody program
OREGA Biotech announces today an exclusive license agreement under which OREGA Biotech grants Genmab full, worldwide rights to its first-in-class immuno-oncology antibody program against a novel and undisclosed target. This license agreement results from a fruitful...